Tarsus Pharmaceuticals, Inc. TARS Clinical Milestones — Contractual milestone payment net sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept tars:CollaborativeArrangementRightsAndObligationsContractualMilestoneNetSales.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
The Company made cash payments under the All Human Uses Elanco Agreement of $0.5 million related to a clinical milestone that was triggered in December 2022 upon enrollment of the first patient in the Phase 2a Carpo trial, for the potential treatment of Lyme disease. The Company is required to make potential future cash payments under this agreement upon the achievement of various clinical milestones up to an aggregate maximum of $4.0 million and various commercial and sales threshold milestones for an aggregate maximum of $77.0 million. In addition, the Company will be obligated to pay contractual royalties in the single digits of its product sales, net. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license.
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s clinical milestones — contractual milestone payment net sales?
- Tarsus Pharmaceuticals, Inc. (TARS) reported clinical milestones — contractual milestone payment net sales of $500K in Q2 2026.
- What does clinical milestones — contractual milestone payment net sales mean?
- This metric represents the revenue recognized from milestone payments triggered by the achievement of specific clinical, regulatory, or commercial objectives as defined in licensing or collaboration agreements. It reflects the successful progression of a therapeutic candidate through the development pipeline and the subsequent realization of contractual value. Tracking this helps investors assess the company's ability to convert research and development progress into tangible financial inflows.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s clinical milestones — contractual milestone payment net sales.
Connect your AI assistant and compare it to peers, right in your chat.
